According to GILD’s 1Q16 CC, there are 10-20M HCV patients in China who can afford treatment at "Western" prices; however, genotyping is uncommon, so there’s a need for pan-genotypic regimens.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.